AUM Biosciences is committed to addressing the unmet medical needs by developing innovative and affordable oncology therapeutics for Asia.
AUM Biosciences has raised $27.0M in total funding. The most recent round was Series A. The last funding was announced in October 2021.
AUM Biosciences's investors include Agency for Science, Technology and Research, SPRIM, Everlife.
AUM Biosciences is headquartered in Singapore, Singapore.
AUM Biosciences is committed to addressing the unmet medical needs by developing innovative and affordable oncology therapeutics for Asia.
AUM Biosciences is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AUM Biosciences — Funding & Investors." VCBacked, October 12, 2021, https://www.vcbacked.co/company/aum-biosciences. Accessed August 17, 2026.
VCBacked. (2021). AUM Biosciences — Funding & Investors. Retrieved August 17, 2026, from https://www.vcbacked.co/company/aum-biosciences
{{cite web |title=AUM Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/aum-biosciences |website=VCBacked |access-date=August 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated